MCHENRY, Ill., May 2, 2013 /PRNewswire/ -- Medela today announces the availability of Invia® Motion™ Negative Pressure Wound Therapy (NPWT) System for treating chronic and acute wounds. A personal device for every patient, Invia Motion offers a full choice of therapy options, and promotes improved patient mobility and freedom.
Invia Motion's small and lightweight design helps facilitate wound healing as it allows patients to be fully mobile and continue with normal daily activities. "The portability of the Invia Motion not only protects patient dignity and well-being, but also improves patient compliance which greatly impacts improvement in overall patient outcomes," states Rey Paglinawan, Medela NPWT medical research specialist who assisted in developing the product.
Designed with optimum hygiene in mind, every patient treated with an Invia Motion receives a new device. Each device and accessories provide up to 60 days of therapy which typically covers a patient's entire length of treatment. In addition, the system is flexible in offering a choice of constant or intermittent therapy modes, multiple pressure settings, and multiple drain options that can be used with either antimicrobial gauze or polyurethane foam dressings.
In recent post-market studies performed in the US and EU, patients appreciated the discrete operation of Invia Motion, as well as its quiet operation and simple handling; requiring only a few steps to operate. Clinicians who tested the product reported that the system offers more benefits when compared to similar products. Providing a simple and 'ready-to-go' system with an easy canister replacement technique and a user-friendly interface exceeded clinician and patient expectations during the testing.
With over 50 years of leadership in medical vacuum technology, Medela has proven success in developing innovative and award winning products that deliver Swiss engineering quality and reliability. True NPWT™ by Medela provides clinicians with options in caring for patients that enhance overall therapy performance, help improve patient outcomes, and help control cost.